Janssen Sciences Ireland UC

Lobbying Organisation Janssen Sciences Ireland UC

Date published 19 Jan, 2024

Relevant Matter Legislation

Public Policy Area EU Affairs

Period 1 Sep, 2023 to 31 Dec, 2023

Specific Details Engagement on the EU revision of pharmaceutical legislation

Intended results To ensure that revised EU pharmaceutical legislation continues to support commercial investment and does not reduce existing incentives to innovation.

Name of person primarily responsible for lobbying on this activity Mark Canavan

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Meeting (1)

Conversation with Barry Andrews MEP following an IIEA event in Dublin on the EU Health Union.

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Barry Andrews MEP (European Parliament)